Sermorelin
Also known as: GRF 1-29, GHRH 1-29
Short-acting GHRH analog that stimulates natural pulsatile growth hormone release from the pituitary.
Evidence
Moderate
FDA status
Not FDA-approved
Source
Synthetic GHRH fragment (amino acids 1-29)
Overview
Short-acting GHRH analog that stimulates natural pulsatile growth hormone release from the pituitary.
Mechanism of Action
Binds GHRH receptors to stimulate endogenous GH secretion, preserves natural pulsatile GH patterns, short half-life, maintains hypothalamic-pituitary feedback loops.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Increases natural GH production
- Improves sleep quality
- Recovery
- Muscle mass
- Improves body composition
- Maintains physiologic GH patterns
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Sermorelin can be requested through Gabriel. A licensed clinician at a telehealth partner reviews your request and decides whether it's appropriate. Gabriel never gives peptide dosing.
Compounded medications aren't FDA-approved. A licensed clinician decides what's right for you.
Research & Evidence
Clinical trials, formerly FDA approved
Was FDA-approved (Geref) to test for and treat growth hormone deficiency in children; the maker stopped selling it in 2008. It raises GH and IGF-1 levels. Evidence for anti-aging use is weak.
Safety Information
Potential Side Effects
- •Injection site reactions
- •Flushing
- •Headache
- •Dizziness
- •Hyperactivity
Contraindications
- Active cancer
- Diabetic retinopathy
- Pregnancy
- Breastfeeding
Interactions
- ⚠May affect glucose metabolism
Quick Facts
Related Peptides
CJC-1295
Long-acting GHRH analog that stimulates sustained growth hormone release.
Ipamorelin
Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.
Tesamorelin
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.